Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Serum Amyloid P aa 1 to the C-terminus (N terminal).
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Our Abpromise guarantee covers the use of ab45151 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 25 kDa (predicted molecular weight: 25 kDa).
Unpurified format: 1/1000000
|IHC-P||1/50 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Enzymatic antigen retrieval (using protease) also has been found to work and may acheive better results
Diluting and blocking buffer: 5% NFDM /TBST
ab45151 staining Serum Amyloid P in human endometrial carcinoma tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde and antigen retrieval was by heat mediation in a EDTA buffer. Samples were incubated with primary antibody at a dilution of 1/50. A goat anti-rabbit IgG H&L (HRP) ab97051 was used as the secondary antibody at 1/500.
Negative control 1: PBS in place of primary antibody.
Blocking and diluting buffer: 5% NFDM /TBST